ライフサイエンスコーパス: phase III study

1 TISSE was a randomized, open-label, adaptive phase III study.

2 id hemorrhage, but has yet to be tested in a phase III study.

3 ommended dose for evaluation in a randomized phase III study.

4 on the same schedule, in this international phase III study.

5 mia (CML) were evaluated in an international phase III study.

6 apecitabine were included in this randomized phase III study.

7 ngoing IFM/Dana-Farber Cancer Institute 2009 phase III study.

8 , double-blind, double-dummy, parallel-group phase III study.

9 ts are being investigated further in a large phase III study.

10 o be further confirmed in a large randomized phase III study.

11 benefit but need to be confirmed in a larger phase III study.

12 port end-of-phase II decisions and design of phase III studies.

13 nic symptoms, were enrolled in 2 consecutive phase III studies.

14 he main endpoint to measure effectiveness in phase III studies.

15 phase II studies and underpowered or flawed phase III studies.

16 ariety of clinical trials, including several phase III studies.

17 the efficacy of LDV/SOF regimens in the ION phase III studies.

18 ter transfer protein inhibitors are still in phase III studies.

19 d phase II study and is preferred for future phase III studies.

20 essed by simulating multiple replicas of the phase III studies.

21 r, with a safety profile comparable to prior phase III studies.

22 safety profile comparable with that in prior phase III studies.

23 and week 104 to relapsing MS patients in the phase III study, 166 of whom completed both assessments.

24 In a phase III study, 411 healthy individuals from 19 US site

25 In this open-label, multicenter phase III study, 87 patients with PI aged >/=2 years rec

26 ouble-blind, placebo-controlled, multicenter phase III study, a total of 52 patients with inoperable

27 spective of their JAK2 mutation status, in 2 phase III studies against placebo (COMFORT-I) and best a

28 This double-blind, phase III study aimed to demonstrate that sunitinib plus

29 This phase III study (ALLY-3) evaluated the 12-week regimen o

30 rongly influenced by results of a randomized phase III study among recurrent patients as well as furt

31 ible and relevant primary end point for both phase III studies and phase II studies where a delay in

32 We aimed to confirm these results in a phase III study and investigated a potential clinical be

33 hase II study), latency to persistent sleep (phase III study), and circadian phase shifting (phase II

34 tested in sarcoma patients in a phase II and phase III study, and was shown to prolong progression-fr

35 Complementing these phase III studies are a number of innovative phase II st

36 h remains investigational however, and these phase III studies are critical.

37 Larger phase III studies are needed to ascertain if these acute

38 Phase III studies are needed to define the role of vacci

39 Phase III studies are now beginning to establish firmly

40 sults with cabozantinib are encouraging, and phase III studies are ongoing.

41 s retrospective analysis of three randomized phase III studies assessed the prognostic and predictive

42 This phase III study assessed efficacy and safety of oral, su

43 This phase III study assessed the efficacy of vandetanib vers

44 This phase III study assessed the impact of postoperative adj

45 C30) data were collected prospectively in a phase III study assessing gemcitabine and cisplatin vers

46 Setup of a phase III study at a major cooperative oncology group is

47 Median calendar days to activate a phase III study at CALGB was 580 days (range, 295 to 1,2

48 In the phase III study AVF2107g, bevacizumab (BV) demonstrated

49 have been shown to provide benefit in IBD in phase III studies by blocking other antiinflammatory pat

50 These considerations led to a randomized phase III study by the International Berlin-Frankfurt-Mu

51 ty, with similar effects in the phase II and phase III studies (combined studies: N = 1,395; hazard r

52 omized, controlled, multicenter, open-label, phase III study compared docetaxel versus paclitaxel in

53 This randomized, multicenter, phase III study compared doxorubicin and docetaxel (AT)

54 This open-label, randomized, phase III study compared oral and IV topotecan in patien

55 This open-label, randomized, multicenter phase III study compared oral topotecan/intravenous cisp

56 This prospective multicenter phase III study compared the efficacy and safety of a tr

57 This phase III study compared the efficacy and safety of beva

58 This phase III study compared the efficacy and safety of beva

59 This phase III study compared the efficacy and safety of gemc

60 This phase III study compared the safety and efficacy of the

61 This phase III study compared the time to progression (TTP) o

62 Phase III studies comparing imatinib with nilotinib or d

63 g-term survival and toxicity of a randomized phase III study comparing cisplatin alone with cisplatin

64 Purpose A phase III study comparing eribulin with dacarbazine in p

65 otype with efficacy and toxicity in E2100, a phase III study comparing paclitaxel versus paclitaxel p

66 ods Southwest Oncology Group (SWOG) S0518, a phase III study conducted in a US cooperative group syst

67 ble-blind, placebo-controlled parallel group phase III study conducted in Germany (21 sites), in adul

68 In the phase III study COU-AA-301, abiraterone acetate (AA) plu

69 Validation included analyses of phase III study data sets to determine if the same mutat

70 Recently reported, placebo-controlled phase III studies demonstrate a meaningful progression-f

71 Data from phase III studies demonstrate that with SOF-based regime

72 This large, phase III study demonstrates comparable efficacy of DA Q

73 on is further complicated by the fact that a phase III study designed to compare secondary hormonal t

74 This phase III study documents a role for gemcitabine in adva

75 TS AND METHODS This multicenter, open-label, phase III study enrolled 676 chemotherapy-naive patients

76 s and Methods This randomized, double-blind, phase III study enrolled patients with histologically co

77 In this phase III study, eribulin was not shown to be superior t

78 nt 52-week, double-blind, placebo-controlled phase III study evaluated induction and maintenance trea

79 This phase III study evaluated overall survival (OS) and othe

80 This placebo-controlled phase III study evaluated telotristat ethyl in this sett

81 This phase III study evaluated the efficacy and safety of ear

82 Ten phase III studies evaluating the role of IFN-alpha2 in 1

83 ent-I) is a double-blind, placebo-controlled phase III study evaluating ruxolitinib in patients with

84 A recent phase III study evaluating the combination of lenalidomi

85 We report the results of OPUS-2, a phase III study evaluating the efficacy and safety of li

86 eport the results of OPUS-3 (NCT02284516), a phase III study evaluating the efficacy and safety of li

87 Following completion of phase III studies, eventual new drug application approva

88 The result of a third phase III study examining the effect of tissue factor pa

89 w-up awaits confirmation in the larger-scale phase III study (EXCITE trial) currently in progress.

90 Although a recent phase III study failed to demonstrate any protective eff

91 d phase II trials; although the registration phase III study failed to meet its accrual goals, it did

92 Recent phase III studies, following angiography-based phase I a

93 CDK4/6-selective inhibitor, is currently in phase III studies for ER-positive breast cancer and KRAS

94 We will review ongoing phase III studies for patients in first clinical remissi

95 Future phase III studies for patients with AA may need to consi

96 ue, FTY720 (fingolimod), a drug currently in phase III studies for treatment of multiple sclerosis, h

97 size and survival time distributions in the phase III study for both capecitabine and FU were consis

98 pancreatic NET, the longest OS reported in a phase III study for this population.

99 Furthermore, phase III studies frequently fail to achieve their plann

100 t antitumor response and overall survival in phase III studies from longitudinal tumor size data in p

101 This double blind, placebo controlled, phase III study had a screening period, a 2 week dose ti

102 A set of confirmatory phase III studies has been initiated to determine whethe

103 Recent clinical evidence from phase III studies has shown that nintedanib has signific

104 randomized, double-blind, placebo-controlled phase III study has since been conducted in patients wit

105 of rheumatoid arthritis - over the past year phase III studies have demonstrated impressive improveme

106 hoice of nonvalidated scientific targets for phase III studies have hampered progress and created mis

107 Phase III studies have yet to be undertaken for these no

108 Recent results from a phase III study have indicated that treatment of patient

109 but are frequently followed by unsuccessful phase III studies, highlighting a disconnect in the tran

110 aluations, with four positive reports in six phase III studies identified.

111 analyzed five randomized, placebo-controlled phase III studies in 4,205 patients with breast, colorec

112 evaluated as a monotherapy in two randomized phase III studies in advanced NSCLC.

113 Accrual to national phase III studies in early disease is now critical and s

114 Phase III studies in patients with multiple myeloma and

115 l compared with docetaxel in two independent phase III studies in previously treated patients with ad

116 enter, randomized, controlled, double-blind, phase III study in 704 patients with chronic hepatitis C

117 BENEFIT is a randomized 3 year, phase III study in adults receiving a kidney transplant

118 alization (MMSE) in a randomized prospective phase III study in mCRC.

119 ed with single-agent rituximab in an ongoing phase III study in relapsed FL.

120 oGRession in Multiple SclerOsis (ALLEGRO), a phase III study in relapsing-remitting multiple sclerosi

121 th FCAS, and the data led to the design of a phase III study in this patient population.

122 VIKING-3 is a single-arm, open-label phase III study in which therapy-experienced adults with

123 We did a phase III study in which we used a (123)I-FP-CIT SPECT s

124 The recent completion of several phase III studies, including those evaluating octreotide

125 In a parallel phase III study, Intergroup N9741, oxaliplatin plus fluo

126 This placebo-controlled phase III study investigated the effect on survival of g

127 This phase III study investigated whether continuation mainte

128 Newer phase III studies involve the use of new systemic agents

129 Results of Phase III studies involving a large number of Alzheimer'

130 lignant glioma and suggest that a randomized phase III study is indicated.

131 A phase III study is ongoing.

132 umor response and survival in an independent phase III study (n = 1,000 replicates) of capecitabine v

133 A global phase III study (NCT02312206) has been initiated.

134 f genotypes in patients from 2 multinational phase III studies of adefovir dipivoxil.

135 Phase III studies of an oral, live, pentavalent, human-b

136 There are no published randomized phase III studies of bladder, cervical, endometrial, and

137 By contrast, two phase III studies of GVAX, an allogeneic tumor cell vacc

138 We discuss the phase II and phase III studies of hepatic-arterial infusion therapy,

139 A recent randomized phase III study of 719 de novo liver transplant recipien

140 patients entered into a multi-institutional Phase III study of adjuvant therapy for colon cancer.

141 phase II study of cetuximab and a randomized phase III study of bevacizumab.

142 Using data from the 1-year phase III study of deferasirox, including volumes of tra

143 sier Oncology Group designed this randomized phase III study of gemcitabine plus cisplatin compared w

144 The phase III study of hydroxyurea in infants (BABY HUG) has

145 A phase III study of IL-2 is now warranted.

146 On the basis of these observations, a phase III study of low-dose rivaroxaban as adjunctive th

147 s participating in a double blind randomized Phase III study of neoadjuvant endocrine therapy.

148 A phase III study of palliative liver RT is planned.

149 andomized, double-blind, placebo-controlled, phase III study of rituximab therapy.

150 A global phase III study of S-1 plus cisplatin versus fluorouraci

151 A phase III study of TH-302 is ongoing (NCT01440088).

152 In a post hoc analysis of data from a phase III study of the effects of teduglutide on patient

153 This first phase III study on a topical inhibitor of corneal angiog

154 long-term follow-up findings of a randomized phase III study on the addition of six cycles of procarb

155 In this phase III study patients were randomized to receive 6 su

156 andomized, double-blind, placebo-controlled, phase III study, patients received intravenous docetaxel

157 In this phase III study, patients were randomly assigned to open

158 In a randomized, open-label, multicenter, phase III study, patients with previously untreated pred

159 As part of phase III studies, plasma and fecal samples were analyze

160 e recently published results of a randomized phase III study prompted an update of this guideline.

161 This multicenter, open-label, phase III study randomly assigned patients in a 1:2 rati

162 The CONKO-003 phase III study reported a survival benefit with second-

163 OG 8802, 9506, 9706, 9906, and 0233) and one phase III study (RTOG 8903).

164 lar endothelial growth factor antibody, in a phase III study, showed significantly improved overall a

165 Phase III studies support chemoimmunotherapy as the init

166 In the phase III study, tasimelteon improved sleep latency, sle

167 This phase III study tested the hypothesis that the CA-125-sp

168 Definitive phase III studies testing the hypothesis that this appro

169 itudinal tumor size models and data from two phase III studies that compared bevacizumab plus chemoth

170 Recently, data from two randomized phase III studies that compared docetaxel-based chemothe

171 We report a multicenter phase III study that compared pegylated liposomal doxoru

172 m a theoretical perspective or in randomized phase III studies, there are little data to demonstrate

173 In the absence of a phase III study, this new combined treatment should be r

174 Two completed randomized phase III studies to be reported in mid-2004 will more d

175 nt populations, mitigating the need for full Phase III studies to test the hypothesis.

176 (A phase III study to compare SonoVue(R) enhanced myocardia

177 then undertook a multicentric international phase III study to compare three and five cycles of the

178 Phase III study to confirm a trend observed in a previou

179 efficacy and physiological mechanism, and a phase III study to confirm efficacy of the melatonin ago

180 randomized, double-blind, placebo-controlled phase III study to test whether the administration of in

181 The IELSG-19 phase III study, to our knowledge, was the first such st

182 In phase III studies, treatment with the once-daily fixed-d

183 in sepsis, the positive outcome of a recent phase III study using activated protein C (APC) has led

184 A pivotal phase III study using Sipuleucel-T, an autologous prosta

185 This open, randomized, phase III study was carried out in 71 centers.

186 A randomized, open-label, phase III study was conducted in 16 institutions through

187 of historical etoposide-platinum controls, a phase III study was conducted to compare pemetrexed-carb

188 ), this randomized, double-blind, controlled phase III study was conducted to confirm the efficacy an

189 This phase III study was conducted to confirm the phase II re

190 A double-blind, placebo-controlled phase III study was performed to assess whether basilixi

191 This phase III study was performed to confirm preclinical stu

192 randomized, double-blind, placebo-controlled phase III study was performed to establish definitively

193 The objective of this phase III study was to determine the efficacy, safety, a

194 A phase III study was undertaken to evaluate the safety an

195 Oncology Group study AHOD0031, a randomized phase III study, was designed to evaluate the role of ea

196 Thirteen phase III studies were activated by CALGB during the stu

197 Heart Failure) phase II study and RELAX-AHF phase III study were international, multicenter, double-

198 A larger phase III study will be necessary to determine whether t

199 A series of phase III studies with these antibodies and direct tyros

200 We undertook an open-label phase III study with recruitment between March 1, 2004,

201 rt of 287 patients treated in a multicenter, phase III study with single-agent irinotecan administere